Klinische Studie NCT05132075 · Non-Small Cell Lung Cancer

Klinische Studie NCT05132075 (Phase III) ist «aktiv (nicht rekrutierend)» auf ClinicalTrials.gov.

Erkrankung: Non-Small Cell Lung Cancer · Registrierte Interventionen: JDQ443, docetaxel · Erfasste Daten (Quelle): 2022-06-15, 2026-09-03, 2021-11-24, 2026-09-25.

Studienzusammenfassung (Quelle: ClinicalTrials.gov, Originaltext auf Englisch):

This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.

Quelle: https://clinicaltrials.gov/study/NCT05132075